key: cord-0686583-hovl15pa
authors: Wolff, M. J.; Gilabert, M.; Hernandez, R.
title: Clinical outcomes in hospitalized vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalized adults
date: 2022-02-08
journal: nan
DOI: 10.1101/2022.02.07.22270555
sha: 8951c264a0990947b1aa946e1ce48c228da6878a
doc_id: 686583
cord_uid: hovl15pa

The inactivated SARS-CoV-2 vaccine (CoronaVac TM) has been the principal vaccine used in the Chilean pre-booster immunization campaign. We compared major outcomes in 260 hospitalized vaccinated vs 507 unvaccinated adults with COVID-19 (mid-2021). The vaccinated group was much older, required less critical care, had lower hospital mortality (adjusted by age), and had shorter hospitalization than the unvaccinated. Benefits were most pronounced in those older than 59 years

strain and the subsequent variants like delta and omicron (1, 2) . Nonetheless, breakthrough cases occur since vaccines do not confer sterilizing immunity; cases following mRNAbased vaccines are far less likely to be severe.

Chile has implemented an early and expansive vaccination program that enabled two-dose immunization in 88% of its 19.5 million population, older children included, by end of the third quarter of 2021 (3). CoronaVac® (Sinovac Biotech Ltd, Beijing, China) is an inactivated vaccine that has been the cornerstone of the program, used in 75% of vaccinated adults. BNT162b2 (Pfizer with BioNTech and Fosun Pharma, New York, NY, USA) mRNA vaccine has been used mostly in immunocompromised adults and minors.

CoronaVac immunogenicity is comparatively less robust, though substantial antibody levels are achieved; real-world effectiveness was assessed in a Chilean study of 4 million vaccinees demonstrating a 65.9% (95% CI 65.2-66.6) preventive effect for symptomatic . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) A case of COVID-19 was defined by a positive PCR or characteristic clinical and radiologic findings. Accurate information on the type, number, and date of vaccination doses was provided from a mandatory nationwide registry. Our local ethics committee authorized use of these data for outcomes research and waived the need for informed consent, under conditions guaranteeing data confidentiality and patient anonymity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (Table) . Total mean (and median) length of stay in days were 11.7 (9) of Fvac and 12.6 (10) for Unvac; for those age >60 years Fvac length of stay was 12.8 (10) days and 17.8 (15) days for Unvac (p < 0.001; Table) .

Discussion: This study of adults hospitalized for COVID-19 during the second wave in Chile found that hospitalizations, CCU admissions, and ventilator use were all more common in unvaccinated people at a time when the majority of the adult population had been vaccinated with inactivated SARS-CoV-2 vaccines. When age is considered, deaths are also lower with immunization. The U.S. Centers for Disease Control and Prevention has reported similar results with mRNA vaccine use (6). We believe that the good performance of the less potent inactivated vaccine is important for China and the >45 low-and middle-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint income countries (LMIC) that use World Health Organization-approved inactivated vaccines as the backbone of their vaccine efforts (7). Chilean data have confirmed inactivated vaccine efficacy in clinical trials (8) and effectiveness for multiple outcomes in a state sponsored vaccination programs in > 4 million people (4). Our study demonstrates the value of inactivated vaccines in reducing severity of disease in hospitalized patients with COVID-19 at multiple age strata. Among the hospitalized COVID-19 cases, one in four had received full primary vaccination, overwhelmingly CoronaVac (96.5%), much higher than its 75% participation in the mix of vaccines used in the country consistent with the much higher hospitalization prevention effect found with BNT162b2 in the country compared with the former during the same period of this study (97.2% vs 86%) (5).

Our vaccinated hospitalized subjects were two decades older, on average, than the unvaccinated hospitalized subjects, almost certainly representing a population with more baseline comorbidities and naturally more prone to have severe disease and death when infected compared to younger people. The higher mortality in the vaccinated group as a whole is misleading; once age is controlled for by stratum-specific analyses, death rates in each decade group from the 40s to the 70s were lower in vaccinees, with too few cases > 80 years in the unvaccinated group for meaningful comparisons. This older cohort also had fewer admissions to CCUs, less need for mechanical ventilation and shorter lengths of hospital stay as a whole; these differences were most pronounced and statistically significant in those older than 59 years of age. These clinical outcomes data suggest that full prior vaccination with the inactivated vaccine provides a significant protection from serious disease. At a national level, the aggressive vaccination program in Chile of early 2021 seems to have blunted the magnitude of the epidemic, including the more salutary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint consequences for those with breakthrough disease, reinforcing confidence in the vaccines used. We will be unable to follow-up this study since unvaccinated persons are now scarce with special incentives towards vaccination and restrictions on the unvaccinated being put in place for adults and children in a national effort to maximize immunization in the The global community may wish to consider mRNA boosters for persons with primary vaccination with inactivated vaccines, given highly favorable immunological results of this combination noted from the Dominican Republic (9) and enhanced preventive effectiveness from Chile (10).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 11.7 (9) 12.6 (10) 0.35 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint

et als for the COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

-Chile´s Ministry of Health daily official report

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Chile´s Ministry of Health. Effectiveness of the SARS-CoV-2 vaccine program

2%) COVID-19 admissions in adults with incomplete vaccination and/or <14 days of last dose at COVID-19 diagnosis; these patients were not eligible for the study CCU: Critical Care Unit

Prevention. MMWR / September 17, 2021 / Vol. 70 / No. 37 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint 7.-World Health organization: https://www.who.int/news/item/01-06-2021-who-validatessinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 8, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint Table. Comparative data in hospitalized COVID-19 patients in Chile with and without full SARS-CoV-2 vaccination prior to diagnosis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted February 8, 2022. ; https://doi.org/10.1101/2022.02.07.22270555 doi: medRxiv preprint